Merck KGaA inks deal worth up to $830M with Cambridge cancer biotech


Cancer firm Mersana Therapeutics has scored a collaboration deal worth up to $830 million with Merck KGaA, the German pharmaceutical giant.

Previous Taber's Wharf Partners chosen to redevelop New Bedford State Pier
Next Humana lands $71 billion contract from the Department of Defense